MXPA05005772A - Bromhidrato de escitalopram y un metodo para su preparacion. - Google Patents
Bromhidrato de escitalopram y un metodo para su preparacion.Info
- Publication number
- MXPA05005772A MXPA05005772A MXPA05005772A MXPA05005772A MXPA05005772A MX PA05005772 A MXPA05005772 A MX PA05005772A MX PA05005772 A MXPA05005772 A MX PA05005772A MX PA05005772 A MXPA05005772 A MX PA05005772A MX PA05005772 A MXPA05005772 A MX PA05005772A
- Authority
- MX
- Mexico
- Prior art keywords
- escitalopram
- disorder
- hydrobromide
- disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200202005 | 2002-12-23 | ||
| PCT/DK2003/000902 WO2004056791A1 (en) | 2002-12-23 | 2003-12-18 | Escitalopram hydrobromide and a method for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05005772A true MXPA05005772A (es) | 2005-08-16 |
Family
ID=32668635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05005772A MXPA05005772A (es) | 2002-12-23 | 2003-12-18 | Bromhidrato de escitalopram y un metodo para su preparacion. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040167209A1 (enExample) |
| EP (1) | EP1578738B1 (enExample) |
| JP (2) | JP4658613B2 (enExample) |
| KR (1) | KR20050086933A (enExample) |
| CN (1) | CN100349885C (enExample) |
| AR (1) | AR042652A1 (enExample) |
| AT (1) | ATE388947T1 (enExample) |
| AU (1) | AU2003287919B2 (enExample) |
| BR (1) | BR0317623A (enExample) |
| CA (1) | CA2511142A1 (enExample) |
| CY (1) | CY1107451T1 (enExample) |
| DE (1) | DE60319739T2 (enExample) |
| DK (1) | DK1578738T3 (enExample) |
| EA (1) | EA013116B1 (enExample) |
| EG (1) | EG24729A (enExample) |
| ES (1) | ES2298595T3 (enExample) |
| IL (1) | IL169125A0 (enExample) |
| IS (1) | IS2654B (enExample) |
| ME (1) | MEP5808A (enExample) |
| MX (1) | MXPA05005772A (enExample) |
| MY (1) | MY135468A (enExample) |
| NO (1) | NO20053595L (enExample) |
| NZ (1) | NZ540281A (enExample) |
| PE (1) | PE20040924A1 (enExample) |
| PL (1) | PL378275A1 (enExample) |
| PT (1) | PT1578738E (enExample) |
| RS (1) | RS51092B (enExample) |
| TW (1) | TW200501943A (enExample) |
| UA (1) | UA80170C2 (enExample) |
| UY (1) | UY28148A1 (enExample) |
| WO (1) | WO2004056791A1 (enExample) |
| ZA (1) | ZA200504109B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0317623A (pt) * | 2002-12-23 | 2005-11-29 | Lundbeck & Co As H | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| NZ549100A (en) * | 2004-03-05 | 2010-02-26 | Lundbeck & Co As H | Crystalline composition containing escitalopram oxalate |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
| EP1954257A4 (en) * | 2005-10-14 | 2009-05-20 | Lundbeck & Co As H | METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| JP5501615B2 (ja) * | 2006-07-11 | 2014-05-28 | 田辺三菱製薬株式会社 | モルホリン化合物の塩 |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
| CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
| RU2020111694A (ru) * | 2017-10-09 | 2021-11-12 | Тева Фармасьютикал Индастриз Лтд. | Новые соли и твердые формы эсциталопрама |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34712A (en) * | 1862-03-18 | James h | ||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| ATE230738T1 (de) * | 1998-10-20 | 2003-01-15 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| PT1298124E (pt) * | 1999-10-25 | 2007-05-31 | Lundbeck & Co As H | Método para a preparação de citalopram |
| US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
| IES20010693A2 (en) * | 2000-08-10 | 2002-07-10 | Lundbeck & Co As H | Pharmaceutical composition containing citalopram |
| WO2002046340A1 (de) * | 2000-12-04 | 2002-06-13 | Dr. Frische Gmbh | Verfahren zur herstellung von fettsaüreestern |
| MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
| AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
| BR0317623A (pt) * | 2002-12-23 | 2005-11-29 | Lundbeck & Co As H | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram |
| US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en not_active Ceased
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Ceased
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011037893A (ja) | 臭化水素酸エスシタロプラム（ｅｓｃｉｔａｌｏｐｒａｍｈｙｄｒｏｂｒｏｍｉｄｅ）およびその製造方法 | |
| CA2359810C (en) | Process for the preparation of pure citalopram | |
| UA71634C2 (uk) | Спосіб одержання чистого циталопраму | |
| SK512004A3 (en) | Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram | |
| WO2001051478A1 (en) | Method for the preparation of citalopram | |
| NZ580738A (en) | Process for the preparation of escitalopram | |
| JPH08510477A (ja) | 新規なｎ−ベンゾイルメチル−ピペリジン類 | |
| HK1087708B (en) | Escitalopram hydrobromide and a method for the preparation thereof | |
| EP1485367B1 (en) | Purified citalopram salts | |
| WO2003042202A1 (en) | Isobenzofuran derivatives | |
| NO331657B1 (no) | Fremgangsmate for fremstilling av iohexol | |
| EP1140912A1 (en) | Process for the preparation of an acetate salt of paroxetine or paroxetine analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |